Presenting features and treatment outcome of acute promyelocytic leukemia arising after multiple sclerosis

Haematologica

Volumn 96, Issue 4, 2011, Pages 621-625

  Ammatuna, Emanuele ^a,b   Montesinos, Pau ^c   Hasan, Syed Khizer ^a,b   Ramadan, Safaa M ^a,b   Esteve, Jordi ^d   Hubmann, Maximillian ^e   Pagoni, Maria ^f   Grimwade, David ^g   Sanz, Miguel Angel ^c   Lo Coco, Francesco ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e UNIVERSITY OF MUNICH   (Germany)

^f EVANGELISMOS HOSPITAL   (Greece)

^g KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Acute promyelocytic leukemia; Multiple sclerosis; Secondary leukemia

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; AZATHIOPRINE; BETA INTERFERON; BREAKPOINT CLUSTER REGION PROTEIN; GLATIRAMER; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; PREDNISONE; RETINOIC ACID;

ADULT; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; GENE; GENE IDENTIFICATION; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALE; MULTIPLE SCLEROSIS; OVERALL SURVIVAL; PML GENE; PROMYELOCYTIC LEUKEMIA; RARA GENE; SECOND CANCER; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79953888314     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.036657     Document Type: Article

References (22)

1. Pollicardo N, O'Brien S, Estey EH, al-Bitar M, Pierce S, Keating M, et al. Secondary acute promyelocytic leukemia: characteristics and prognosis of 14 patients from a single institution. Leukemia. 1996;10(1): 27-31.
2. Pulsoni A, Pagano L, Lo Coco F, Avvisati G, Mele L, Di Bona E, et al. Clinico-biological features and outcome of acute promyelo-cytic leukemia occurring as a second tumor: the GIMEMA experience. Blood. 2002;100 (6):1972-6.
3. Beaumont M, Sanz M, Carli PM, Maloisel F, Thomas X, Detourmignies L, et al. Therapy related acute promyelocytic leukemia. J Clin Oncol. 2003;21(11):2123-37.
4. Pedersen-Bjergaard J, Christiansen DH, Desta F, Andersen MK. Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia. 2006;20(11):1943-9.
5. Mistry AR, Felix CA, Whitmarsh RJ, Mason A, Reiter A, Cassinat B, et al. DNA Topoisomerase II in Therapy-Related Acute Promyelocytic Leukemia. N Engl J Med. 2005;352(15):1529-38.
6. Pascual AM, Téllez N, Boscá I, Mallada J, Belenguer A, Abellán I, et al. Revision of the risk of secondary leukaemia after mitox-antrone in multiple sclerosis populations is required. Mult Scler. 2009;15(11): 1303-10.
7. Goodin DS, Arnason BG, Coyle PK, Frohman EM, Paty DW. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology, Neurology. 2003;61(10):1332-8.
8. Hasan SK, Mays AN, Ottone T, Ledda A, La Nasa G, Cattaneo C, et al. Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. Blood. 2008;112(8):3383-90.
9. Hasan SK, Ottone T, Schlenk RF, Xiao Y, Wiemels JL, Mitra ME, et al. Analysis of t(15;17) Chromosomal Breakpoint Sequences in Therapy-related Versus de novo Acute Promyelocytic Leukemia: Association of DNA Breaks with Specific DNA Motifs at PML and RARA Loci. Genes Chromosomes Cancer. 2010;49(8): 726-32.
10. van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13(12):1901-28.
11. Noguera NI, Breccia M, Divona M, Diverio D, Costa V, De Santis S, et al. Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol. Leukemia. 2002;16(11):2185-9.
12. Lo-Coco F, Avvisati G, Vignetti M, Breccia M, Gallo E, Rambaldi A, et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adult patients younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood. 2010;116(17):3171-9.
13. Sanz MA, Montesinos P, Rayón C, Holowiecka A, de la Serna J, Milone G, et al. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood. 2010; 115(25):5137-46.
14. Sanz MA, Martín G, González M, León A, Rayón C, Rivas C, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracy-cline monochemotherapy: a multicenter study by the PETHEMA Group. Blood. 2004;103(4):1237-43.
15. Burnett AK, Hills RK, Grimwade D. Idarubicin and ATRA is as effective as MRC chemotherapy in patients with acute promyelocytic leukaemia with lower toxic-ity and resource usage: Preliminary results of the MRC AML15 trial. Blood. 2007; 110:181a, abstr 589.
16. Lengfelder E, Haferlach C, Saussele S, Haferlach T, Schultheis B, Schnittger S, et al. German AML Cooperative Group. High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG. Leukemia. 2009;23(12):2248-58.
17. Kaplan EL, Meier P. Nonparametric estimations from incomplete observations. J Am Stat Assoc. 1958;53(282):457-81.
18. Gray RJ. A class of K-sample test for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16(3):1141-54.
19. Pepe MS, Mori M. Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data? Stat Med. 1993;12(8):737-51.
20. Sanz MA, Lo Coco F, Martín G, Avvisati G, Rayón C, Barbui T, et al. Definition of relapse risk and role of non-anthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96(4): 1247-53.
21. Montesinos P, González JD, González J, Rayón C, de Lisa E, Amigo ML, et al. Therapy-Related Myeloid Neoplasms in Patients With Acute Promyelocytic Leukemia Treated With All-Trans-Retinoic Acid and Anthracycline-Based Chemotherapy. J Clin Oncol. 2010;28(24): 3872-9.
22. Dayyani F, Kantarjian H, O'Brien S, Pierce S, Jones D, Faderl S, et al. Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy. Cancer. 2011; 117(1):110-5.